

Special Issue

MERS-CoV

Message from the Guest Editors

Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerged coronavirus: It was identified in 2012 and has, so far, caused over 2100 infections and ~35% fatality rate in humans. People infected with MERS-CoV often develop severe acute respiratory illness, including fever, cough, and shortness of breath. MERS-CoV enters cells by binding to its host receptor dipeptidyl peptidase 4 and fusing viral and host membranes, before it replicates itself inside cells. Recent advances in structural biology have enhanced our understanding of the viral entry and replication processes. Vaccines and therapeutics against MERS-CoV are being developed, although none is clinically available. With the continual threat of MERS-CoV, there is a great need to summarize current progresses and discuss future prospects of MERS-CoV research. In this Special Issue, we welcome the MERS-CoV community to submit research papers or review articles on recent advances of MERS-CoV research. Dr. Fang Li

Guest Editors

Dr. Fang Li

Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA

Dr. Lanying Du

Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA

Deadline for manuscript submissions

closed (30 November 2018)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/14485

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://viruses.mdpi.com)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).